Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
712
datasets available to search
ShareScore release 0.9.0
Dataset results
712 results for “mantle”
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
ClinicalTrials.gov study NCT01661881. IPD Sharing: NO. Countries: 1. Publications: 2.
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
ClinicalTrials.gov study NCT01236391. IPD Sharing: Not stated. Countries: 4. Publications: 3.
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMER
ClinicalTrials.gov study NCT00737529. IPD Sharing: Not stated. Countries: 14. Publications: 4.
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00201877. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
ClinicalTrials.gov study NCT03112174. IPD Sharing: Not stated. Countries: 17. Publications: 2.
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
ClinicalTrials.gov study NCT00878254. IPD Sharing: NO. Countries: 1. Publications: 1.
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
ClinicalTrials.gov study NCT03206970. IPD Sharing: YES. Countries: 1. Publications: 4.
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT00294632. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
ClinicalTrials.gov study NCT01776840. IPD Sharing: Not stated. Countries: 28. Publications: 1.
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
ClinicalTrials.gov study NCT00088205. IPD Sharing: Not stated. Countries: 4. Publications: 1.
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
ClinicalTrials.gov study NCT00114738. IPD Sharing: NO. Countries: 1. Publications: 6.
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
ClinicalTrials.gov study NCT01646021. IPD Sharing: Not stated. Countries: 21. Publications: 2.
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
ClinicalTrials.gov study NCT00601718. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
ClinicalTrials.gov study NCT00420056. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
ClinicalTrials.gov study NCT00980395. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
ClinicalTrials.gov study NCT00633594. IPD Sharing: NO. Countries: 1. Publications: 14.
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
ClinicalTrials.gov study NCT02213926. IPD Sharing: YES. Countries: 10. Publications: 1.
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
ClinicalTrials.gov study NCT02242097. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
ClinicalTrials.gov study NCT00700258. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
ClinicalTrials.gov study NCT00875667. IPD Sharing: Not stated. Countries: 14. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.